The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis

Clinical Biochemistry

Volumn 42, Issue 13-14, 2009, Pages 1352-1357

  Wang, Junjun ^a   Hu, Bing ^a   Meng, Yang ^a   Zhang, Chunni ^a   Li, Ke ^a   Hui, Cai ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Atherosclerosis; Coronary artery disease; Immune complex; Inflammation; Low density lipoprotein; Oxidative modification; Rheumatoid arthritis; Risk factors

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; RHEUMATOID FACTOR; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

ADULT; ANTIGEN-ANTIBODY COMPLEX; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; RHEUMATOID FACTOR;

EID: 69249230900     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.05.016     Document Type: Article

References (34)

1. Van Doornum S., McColl G., and Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum. 46 (2002) 862-873
2. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1776-1785
3. Holvoet P., Mertens A., Verhamme P., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 844-848
4. Holvoet P., Vanhaecke J., Janssens S., Van de Werf F., and Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98 (1998) 1487-1494
5. Tsimikas S., Brilakis E.S., Miller E.R., et al. Oxidized phospholipids, Lp (a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353 (2005) 46-57
6. Lopes-Virella M.F., Griffith R.L., Shunk K.A., and Virella G.T. Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler. Thromb. 11 (1991) 1356-1367
7. Wang J., Qiang H., Zhang C., Liu X., Chen L., and Wang S. Detection of IgG-bound lipoprotein(a) immune complexes in patients with coronary heart disease. Clin. Chem. Acta 327 (2003) 115-122
8. Kim S.H., Lee C.K., Lee E.Y., et al. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol. Int. 24 (2004) 230-233
9. Lourida E.S., Georgiadis A.N., Papavasiliou E.C., Papathanasiou A.I., Drosos A.A., and Tselepis A.D. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized LDL and decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res. Ther. 9 (2007) R19
10. Sherer Y., Gerli R., Vaudo G., et al. Prevalence of antiphospholipid and antioxidized low-density lipoprotein antibodies in rheumatoid arthritis. Ann. N.Y. Acad. Sci. 1051 (2005) 299-303
11. Peters M.J., van Halm V.P., Nurmohamed M.T., et al. Relations between autoantibodies against oxidized low-density lipoprotein, Inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J. Rheumatol. 35 (2008) 1495-1499
12. Cvetkovic J.T., Wållberg-Jonsson S., Ahmed E., Rantapää-Dahlqvist S., and Lefvert A.K. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology (Oxford) 41 (2002) 988-995
13. Wada Y., Kuroda T., Murasawa A., Tanabe N., Nakano M., and Gejyo F. Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 23 (2005) 482-486
14. Sherer Y., Gerli R., Gilburd B., et al. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 16 (2007) 259-264
15. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31 (1988) 315-324
16. Virella G., Derrick M.B., Pate V., Chassereau C., Thorpe S.R., and Lopes-Virella M.F. Development of capture assays for different modifications of human low-density lipoprotein. Clin. Diagn. Lab. Immunol. 12 (2005) 68-75
17. Zhou Z., Wang J., Fu L., and Zhang C. Development of ELISA for oxidized, malondialdehyde-modified LDL and clinical value. Chinese J. Clin. Lab. Sci. 25 (2007) 241-243 (in Chinese)
18. Haberland M.E., Fogelman A.M., and Edwards P.A. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 1712-1716
19. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
20. Boers M., Nurmohamed M.T., Doelman C.J., et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62 (2003) 842-845
21. Park Y.B., Lee S.K., Lee W.K., et al. Lipid profiles in untreated patients with rheumatoid arthritis. J. Rheumatol. 26 (1999) 1701-1704
22. Park Y.B., Choi H.K., Kim M.Y., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am. J. Med. 113 (2002) 188-193
23. Situnayake R.D., and Kitas G. Dyslipidaemia and rheumatoid arthritis. Ann. Rheum. Dis. 56 (1997) 341-342
24. Wallace D.J., Metzger A.L., Stecher V.J., Turnbull B.A., and Kern P.A. Cholesterol lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids. Am. J. Med. 89 (1990) 322-326
25. Lazarevic M.B., Vitic J., Mladenovic V., Myones B.L., Skosey J.L., and Swendler W.I. Dyslipoporteinemia in the course of active rheumatoid arthritis. Semin. Arthritis Rheum. 22 (1992) 172-180
26. Navab M., Hama S.Y., Hough G.P., Subbanagounder G., Reddy S.T., and Fogelman A.M. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 42 (2001) 1308-1317
27. Van Lenten B.J., Wagner A.C., Anantharamaiah G.M., et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106 (2002) 1127-1132
28. McMahon M., Grossman J., FitzGerald J., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54 (2006) 2541-2549
29. Steinbrecher U.P. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262 (1987) 3603-3608
30. Kotani K., Maekawa M., Kanno T., Kondo A., Toda N., and Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim. Biophys. Acta 1215 (1994) 121-125
31. Holvoet P., Perez G., Zhao Z., Brouwers E., Bemar H., and Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin. Invest. 95 (1995) 2611-2619
32. Wang J., Hu B., Kong L., Cai H., and Zhang C. Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin. Chim. Acta 390 (2008) 67-71
33. Wållberg-Jonsson S., Cvetkovic J.T., Sundqvist K.G., Lefvert A.K., and Rantapää-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J. Rheumatol. 29 (2002) 875-882
34. Memon R.A., Staprans I., Noor M., Holleran W.M., Uchida Y., and Moser A.H. Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1536-1542